Liraglutide and metformin composition
Through the design and preparation of liraglutide metformin composition, the problem of inability to use liraglutide and metformin in the prior art is solved by using specific pharmaceutical salts and coating materials, and the glycemic reduction of significantly improving the therapeutic effect is achieved Effect.
Patent Information
- Application Number
- CN202310650251.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
The existing liraglutide and metformin cannot be used effectively, resulting in poor treatment results. A method is needed to combine it to improve the therapeutic effect.
A liraglutide metformin composition is provided, including a therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof, and is provided by a specific weight ratio and coating material such as N-(8-( 2-hydroxybenzoyl)amino)octanoate and fish oil were prepared into enteric-coated capsules for the use of the combination.
The effective combination of liraglutide and metformin was achieved, which significantly improved the effect of treating hyperglycemia, especially in type 2 diabetes and obesity.
Smart Images

Figure BDA0004264930580000021 
Figure BDA0004264930580000022 
Figure BDA0004264930580000031
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of drug combination, and in particular, relates to a liraglutide-metformin combination. Background Art
[0002] Diabetes is a chronic metabolic disease that poses a serious threat to global health. The ninth edition of the IDF report shows that there are currently 463 million adults suffering from diabetes.
[0003] Biguanide compounds are important drugs for the treatment of diabetes. Common biguanide compounds include metformin and phenformin. Their mechanism of action is to reduce the production of liver glycogen, inhibit the absorption of glucose in the intestine, and increase the peripheral absorption and utilization of glucose, thereby improving insulin sensitivity by increasing peripheral sugar intake and utilization.
[0004] Metformin is the first-line drug for controlling hyperglycemia in patients with T2DM and the basic drug in drug combination. It is recommended by diabetes treatment guidelines in many countries around the world. The 2020 version of the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes points out that metformin is currently the most commonly used hypoglycemic drug, with a variety of potential benefits beyond hypoglycemic effects (such as the treatment of cardiovascular disease, cardiovascular complications of diabetes, etc.), and does not increase the risk of hypoglycemia. If there are no contraindications, metformin should always be retained in the treatment plan for diabetes.
[0005] Liraglutide is a natural human glucagon-like peptide 1 in which the 34th lysine is replaced by arginine, and a glutamic acid-mediated 16-carbon palmitoyl fatty acid side chain is added to the 26th lysine.
[0006] Therefore, how to use liraglutide and metformin in combination to improve the therapeutic effect has always been a problem that needs to be solved in the field. Summary of the invention
[0007] 1. Problems to be solved
[0008] In view of the problem that existing liraglutide and metformin cannot be used in combination, the present invention provides a liraglutide-metformin composition, which comprises a therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof. The composition can realize the combined use of liraglutide and metformin, and effectively improve the therapeutic effect.
[0009] 2. Technical solution
[0010] To solve the above problems, the present invention adopts the following technical solutions.
[0011] In one aspect, the present invention provides a liraglutide-metformin composition, which comprises a therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof.
[0012] Another aspect of the present invention provides a medicine, comprising the composition.
[0013] Another aspect of the present invention provides a liraglutide-metformin composition and a medicine, and use thereof in preparing a medicine for treating or preventing hyperglycemia.
[0014] A liraglutide-metformin composition comprises a therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof.
[0015] Preferably, the composition further comprises N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt and fish oil.
[0016] The structural formula of N-(8-(2-hydroxybenzoyl)amino)caprylate is shown in formula (I):
[0017]
[0018] Preferably, the weight ratio of liraglutide or a pharmaceutically acceptable salt thereof, metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil in the composition is
[0019]
[0020]
[0021] or
[0022]
[0023] or
[0024]
[0025] or
[0026]
[0027] or
[0028]
[0029] Preferably, the composition comprises liraglutide or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil.
[0030]
[0031] or
[0032]
[0033] or
[0034]
[0035] or
[0036]
[0037] or
[0038]
[0039]
[0040] Preferably, the composition comprises liraglutide or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil.
[0041]
[0042] or
[0043]
[0044] or
[0045]
[0046] Preferably, the pharmaceutically acceptable salt of liraglutide in the composition comprises any one or a combination of hydrochloride, acetate, decanoate, benzenesulfonate or caprylate. Preferably, the pharmaceutically acceptable salt of metformin in the composition comprises an inorganic acid salt or an organic acid salt. Preferably, the organic acid salt comprises a saturated fatty acid salt or an unsaturated fatty acid salt. Preferably, the pharmaceutically acceptable salt comprises acetate, hydrochloride, hydroiodide, phosphate, nitrate, sulfate, citrate, lactate, succinate, maleate, malate, isethionate, fumarate, sulfonate, sulfate, methanesulfonate, ethanesulfonate, naphthylsulfonate, valerate, propionate, butyrate, disulfonate, succinate, hydroxyethylsulfonate, fumarate ... Any one or combination of decosapentaenoate, docosahexaenoate, docosapentaenoate, cholate, ursodeoxycholate or malonate. Preferably, the N-(8-(2-hydroxybenzoyl)amino)octanoate in the composition includes N-(8-(2-hydroxybenzoyl)amino)octanoate, which is any one or combination of sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, potassium N-(8-(2-hydroxybenzoyl)amino)octanoate, magnesium N-(8-(2-hydroxybenzoyl)amino)octanoate, calcium N-(8-(2-hydroxybenzoyl)amino)octanoate or ammonium N-(8-(2-hydroxybenzoyl)amino)octanoate.
[0047] A medicine comprising any one of the above-mentioned compositions.
[0048] Preferably, the medicament comprises a coating.
[0049] Preferably, the drug comprises an enteric coating or a gelatin coating.
[0050] Preferably, the drug further comprises a pharmaceutically acceptable excipient.
[0051] Preferably, the pharmaceutically acceptable excipients include plasticizers, preservatives, colorants, lubricants, flavoring agents, excipients, diluents, fragrances, solubilizers or disintegrants.
[0052] Preferably, the drug is in oral or injectable form.
[0053] Preferably, the composition further comprises an enteric coating or a gelatin coating.
[0054] Preferably, the polypeptide composition can be prepared by conventional preparation methods, such as mixing liraglutide, metformin hydrochloride, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil, filling them into capsules, and then enteric coating them.
[0055] Preferably, the coating material may be Eudragit L30D, Eudragit L100, Eudragit S100, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate or shellac.
[0056] Preferably, the coating material may include Eudragit L30D, Talc, and polyethylene glycol, and the coating material is dissolved in dichloromethane and isopropanol to obtain a coating solution, and the coating solution is sprayed onto the capsule surface to obtain an enteric-coated capsule, wherein Eudragit L-100: Talc: polyethylene glycol = 9:1:1 (weight ratio), and dichloromethane / isopropanol = 9:1 (volume ratio).
[0057] Use of any of the above compositions and any of the above drugs in the preparation of drugs for treating or preventing hyperglycemia, preferably, use of any of the above drugs in the preparation of drugs for treating or preventing type 2 diabetes, type 1 diabetes or obesity.
[0058] 3. Beneficial effects
[0059] Compared with the prior art, the present invention has the following beneficial effects:
[0060] (1) The composition of the present invention can achieve the combined use of liraglutide and metformin, effectively improving the therapeutic effect. DETAILED DESCRIPTION
[0061] The present invention is described in detail below.
[0062] Example 1
[0063] Liraglutide 5mg Metformin hydrochloride 250mg Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate 70mg fish oil 30mg
[0064] Preparation method
[0065] 5 mg liraglutide, 250 mg metformin hydrochloride, 70 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 30 mg fish oil were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate was 0.5 ml / min, the coating temperature was 30°C to 40°C, and the coating weight gain was 7%.
[0066] Example 2
[0067] Liraglutide 5mg Metformin hydrochloride 125mg Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate 100mg fish oil 30mg
[0068] Preparation method
[0069] 5 mg liraglutide, 125 mg metformin hydrochloride, 100 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 30 mg fish oil were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate was 0.5 ml / min, the coating temperature was 30°C to 40°C, and the coating weight gain was 7%.
[0070] Example 3
[0071] Liraglutide 7.5mg Metformin hydrochloride 125mg Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate 225mg fish oil 150mg
[0072] Preparation method
[0073] 7.5 mg liraglutide, 125 mg metformin hydrochloride, 225 mg sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 150 mg fish oil were mixed, loaded into a capsule, and coated. The coating solution used for coating was prepared as follows: Eudragit L30D, talcum powder, and polyethylene glycol were weighed, dissolved with dichloromethane and isopropanol to obtain a coating solution, and the coating solution was sprayed onto the surface of the capsule to obtain an enteric-coated capsule. Among them, Eudragit L30D: talcum powder: polyethylene glycol = 9:1:1 (weight ratio), dichloromethane / isopropanol = 9:1 (volume ratio). The coating solution flow rate was 0.5 ml / min, the coating temperature was 30°C to 40°C, and the coating weight gain was 7%.
[0074] Example 4
[0075] Animal experiments
[0076] Experimental methods:
[0077] Establishment of diabetic mouse model:
[0078] 60 rats were fasted for 6 hours, and each rat was intraperitoneally injected with streptozotocin at a dose of 40 mg / kg, once a day. At the same time, they were fed with a high-fat diet, and fasting blood glucose was measured with a Roche blood glucose meter. The fasting blood glucose value was greater than 11.1 mmol / L, which was considered a successful model. 50 rats were successfully modeled. The model mice were randomly divided into 5 groups, group A, group B, group C, group D, and group E (model group). There were 10 rats in each group. Another 10 rats that were not modeled were taken as the normal group.
[0079] Dosage:
[0080] Group A was intragastrically administered with the drug prepared in Example 1 at 50 mg / kg based on rat body weight for 6 consecutive weeks with normal drinking water and high-fat diet;
[0081] Group B was intragastrically administered the drug prepared in Example 2 at 50 mg / kg based on rat body weight for 6 consecutive weeks with normal drinking water and high-fat diet;
[0082] Group C was intragastrically administered the drug prepared in Example 3 at 50 mg / kg based on rat body weight for 6 consecutive weeks with normal drinking water and high-fat diet;
[0083] Group D was gavaged with commercially available metformin tablets by catheter, 50 mg / kg based on rat body weight, for 6 consecutive weeks, with normal drinking water and high-fat diet;
[0084] The E group (model group) was intragastrically administered with 0.9% saline daily for 6 consecutive weeks, with normal drinking water and high-fat diet.
[0085] The normal group was gavaged with 0.9% saline daily for 6 consecutive weeks, and was fed with normal drinking water and normal feed.
[0086] Note: 50mg / kg refers to the dosage of metformin hydrochloride 50mg / Kg. The standard average weight of rats is about 200g. For example, in group A, the dosage of metformin hydrochloride is 50mg / Kg, then 10mg of metformin hydrochloride is used, and liraglutide, sodium N-(8-(2-hydroxybenzoyl)amino)octanoate and fish oil are converted according to the corresponding proportions, such as 0.2mg of liraglutide, 2.8mg of sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, and 1.2mg of fish oil. The same calculation is applied to groups B, C and D.
[0087] Blood Glucose Monitoring:
[0088] The blood glucose levels of the animals in each group were measured at 0, 2, 4 and 6 weeks after administration. Blood glucose was measured using a blood glucose meter.
[0089] in conclusion:
[0090] At week 0 (before administration), the average blood glucose values of groups A, B, C, D, and E were compared with those of the normal group, P < 0.05, indicating that the model was successfully established.
[0091] In the 6th week, the average blood sugar levels of group A, group B, group C, and group D were compared with those of group E, P < 0.05, indicating that group A, group B, group C, and group D had a significant blood sugar lowering effect.
[0092] At week 6, the average blood sugar levels of groups A, B, and C were compared with those of group D, P < 0.05, indicating that liraglutide and metformin can synergistically lower blood sugar levels after oral administration, and the blood sugar lowering effect is significant. Among them, group B has the best blood sugar lowering effect.
Claims
1. A liraglutide-metformin composition, comprising a therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof.
2. The composition according to claim 1, further comprising N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil.
3. The composition according to claim 2, wherein the weight ratio of liraglutide or a pharmaceutically acceptable salt thereof, metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil in the composition is or or or or 4. The composition according to claim 3, wherein the composition comprises liraglutide or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil. or or or or 5. The composition according to claim 4, wherein the composition comprises liraglutide or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, N-(8-(2-hydroxybenzoyl)amino)caprylate and fish oil. or or 6. The composition according to any one of claims 1 to 5, wherein the pharmaceutically acceptable salt of liraglutide in the composition comprises any one or a combination of hydrochloride, acetate, decanoate, benzenesulfonate or caprylate, preferably, the pharmaceutically acceptable salt of metformin in the composition comprises an inorganic acid salt or an organic acid salt, preferably, the organic acid salt comprises a saturated fatty acid salt or an unsaturated fatty acid salt, preferably, the pharmaceutically acceptable salt comprises acetate, hydrochloride, hydroiodide, phosphate, nitrate, sulfate, citrate, lactate, succinate, maleate, malate, isethionate, fumarate, sulfonate, sulfate, methanesulfonate, ethanesulfonate, naphthylate, valerate, Any one or combination of propionate, butyrate, eicosapentaenoate, docosahexaenoate, docosapentaenoate, cholate, ursodeoxycholate or malonate. Preferably, the N-(8-(2-hydroxybenzoyl)amino)octanoate in the composition includes N-(8-(2-hydroxybenzoyl)amino)octanoate, which is any one or combination of sodium N-(8-(2-hydroxybenzoyl)amino)octanoate, potassium N-(8-(2-hydroxybenzoyl)amino)octanoate, magnesium N-(8-(2-hydroxybenzoyl)amino)octanoate, calcium N-(8-(2-hydroxybenzoyl)amino)octanoate or ammonium N-(8-(2-hydroxybenzoyl)amino)octanoate.
7. A medicine, comprising the composition according to any one of claims 1 to 6, preferably, the medicine comprises a coating, preferably, the coating comprises an enteric coating or a gelatin coating.
8. The drug according to claim 7, further comprising a pharmaceutically acceptable excipient, preferably, the pharmaceutically acceptable excipient comprises a plasticizer, a preservative, a colorant, a lubricant, a flavoring agent, an excipient, a diluent, a fragrance, a solubilizer or a disintegrant.
9. The drug according to claim 7 or 8, which is in oral or injection form.
10. Use of the composition according to any one of claims 1 to 6 and the drug according to any one of claims 7 to 9 in the preparation of a drug for treating or preventing hyperglycemia, preferably, in the preparation of a drug for treating or preventing type 2 diabetes, type 1 diabetes or obesity.
